On the fly News and insights, exclusive to thefly.com


Plus Therapeutics

$15.27 /

+11.39 (+293.56%)


Plus Therapeutics soars 270% after reporting Q2 earnings results

Shares of pharmaceutical company Plus Therapeutics rose over 270% in Friday trading after the company reported its second quarter financial results after the market close on Thursday. Q2 RESULTS: Plus Therapeutics reported a Q2 net loss per share from continuing operations of ($5.12), with an operating cash burn for the quarter of approximately $1.6M. The company ended Q2 with approximately $4.5M of cash and cash equivalents. LOOKING AHEAD: In the release, Plus Therapeutics said in the second half of the year it intends to submit a Phase 2 clinical trial protocol for its lead pipeline drug, DocePLUS, in Small Cell Lung Cancer patients with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy to the FDA. Furthermore, Plus Therapeutics is pursuing manufacturing and commercial partners for DocePLUS as well as partners for its DoxoPLUS product -- a generic, injectable PEGylated liposomal doxorubicin for multiple cancer types. PRICE ACTION: Shares of Plus Therapeutics rose $10.56, or more than 272%, to $14.44 in Friday trading.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.